Efficacy of Danshen Class Injection in the Treatment of Acute Cerebral Infarction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Table 4

Results of the network meta-analysis of the fibrinogen (lower left quarter).

A
-0.25; (-0.91, 0.40)	B
0.01; (-0.40, 0.44)	0.27; (-0.39, 0.93)	C
-1.09; (-1.37, -0.80)	-0.83; (-1.45, -0.22)	-1.10; (-1.43, -0.78)	D
-0.36; (-0.92, 0.21)	-0.10; (-0.74, 0.53)	-0.37; (-0.94, 0.21)	0.73; (0.18, 1.29)	E
-1.13; (-1.95, -0.29)	-0.88; (-1.92, 0.18)	-1.14; (-2.06, -0.22)	-0.04; (-0.91, 0.83)	-0.77; (-1.77, 0.24)	F
-0.44; (-0.98, 0.10)	-0.19; (-1.05, 0.66)	-0.45; (-1.14, 0.23)	0.65; (0.03, 1.26)	-0.08; (-0.87, 0.69)	0.69; (-0.31, 1.65)	G
-1.79; (-3.51, -0.06)	-1.54; (-3.39, 0.32)	-1.8; (-3.58, -0.02)	-0.70; (-2.45, 1.06)	-1.43; (-3.25, 0.39)	-0.66; (-2.58, 1.27)	-1.35; (-3.14, 0.47)	H

A: WM; B: Danshen injection + WM; C: Fufang Danshen injection + WM; D: Danhong injection + WM; E: Danshenchuanxiongqin injection + WM; F: Sodium Tanshinone IIA Sulfonate injection + WM; G: Salvianolate injection + WM; H: Danshen Salvianolic Acids injection + WM. The result underlined meant it had statistical significant.